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Vitamin A - titne for action
I n the last decade, it has become apparent thatvitamin A, apart from its function in vision, is alsoessential for child health and survival. 1 Available
evidence indicates that marginal vitamin A starus is
associated with an increase in the incidence and severity
of infections, poor growth, iron deficiency anaemia and
excessive childhood monality. Improvement of vitamin
A starus in children results is the enhancement of
growth and iron starus, a decrease in infectious morbi-
dity and, most strikingly, a 30% reduction in overall
childhood mortality rates, according to community-
based studies.' Marginal vitamin A starus is now recog-
nised as a major public health problem in many parts of
the developing world and it is estimated that tens of
millions of children are affected. In addition, clinical
vitamin A deficiency is still one of the leading causes of
childhood blindness in many developing countries, with
over 0,5 million children going blind annually because
of it. Even though the true extent of the problem is not
known in South Africa, limited data' indicate that
marginal vitamin A starus may be a major concern in
this country (G. Hussey, A. Coutsoudis, D. Labadarios
- unpublished data).
In 1983 a longirudinal srudy from Indonesia' repon-
ed that children with marginal vitamin A status had a
significantly greater risk of dying compared with child-
ren not deficient. These findings are consistent with
experimental studies which indicate that vitamin A-
depleted animals die prematurely, usually from over-
whelming sepsis. Subsequent to this srudy, eleven com-
munity-based prophylactic vitamin A supplementation
trials were done worldwide."s In most of these srudies,
children were given vitamin A capsules (lOO 000 -
200 000 IV every 4 - 6 months). Analysis of all of these
studies indicate a significant 30% decrease in the mor-
tality rate of the supplemented children. The reason for
this decline in mortality is probably related to a decrease
in the incidence and severity of infections in the children
given vitamin A.
The association between vitamin A and infection has
been known for over 100 years. Clinicians observed that
common childhood infections frequently precipitated
xerophthalmia and that children who presented with the
latter frequently developed severe and often fatal infec-
tions. In 1928, Green and Mellanby' proposed that vita-
min A be regarded as an anti-infective agent. Scrirnshaw
el al.,' in their review in 1964, evaluated the work of
about 50 researchers, and stated that no nutritional
deficiency is more synergistic with infectious diseases
than that of vitarr'..in A. One of the first recognised fea-
tures of hypovitaminosis A, increased susceptibility to
infection, has had strong confirmation. Recent studies
have reported that children with marginal vitamin A
status have a significantly greater risk of developing
respiratory infections, diarrhoeal disease and severe
measles when compared with children of adequate sta-
tus. Children given vitamin A supplements every 4 - 6
months in community-based studies have been noted to
have a lower prevalence of diarrhoea and pneumonia.'
In pretenn infantS, supplementation has also been asso-
ciated with fewer respiratory tract infections.
Measles is one of the leading causes of childhood
monality; according to the World Health Organisation
it accounts for about 1,2 million deaths annually.
Children at risk of severe measles include those who are
malnourished, the very young and those who are vita-
min A-deficient. Children who are vitamin A-deficient
(even those with marginal status) develop more severe
disease and have a higher case-fatality rate.s Measles is
also a well-recognised precipitating factor for the devel-
opment of xerophthalmia. Ooman el al.' in a global
review of xerophthalmia stated that 'there appears to be
a universal relationship between infectious diseases and
xerophthalmia. This relates especially to measles .. .'
Controlled clinical trials in children hospitalised with
measles have shown that vitamin A supplementation
reduced the monality rate significantly, in some cases by
more than 50%.10 In addition, the severity of complica-
tions such as pneumonia and diarrhoea were also
decreased. The WHOI 1 has recommended vitamin A
supplements for children with severe measles. The dose
recommended is 200 000 IV orally daily for 2 days (in
children under 1 year of age, half the dose is given).
The precise mechanisms by -which vitamin A exens
its newly described effects are not fully understood.
Cenainly, vitamin A is imponant in maintaining the
integrity of epithelial surfaces. 12 Vitamin A deficiency
results in decreased cellular rumover, stratification of
epithelial cells and ultimately squamous metaplasia, ker-
atinisation and desquamation. The net effect of these
changes is loss of the first-line host defence barriers, pre-
disposing the host to infections. In addition, the body's
major defence mechanisms, both cellular and humoral
immune function, are adversely affected.n,I' Children
who are vitamin A-deficient may also not respond ade-
quately to immunisations.
Vitamin A starus can be assessed by clinical criteria
(the WHO's classification of xerophthalmia), tests for
retinal function or conjunctival integrity, assessment of
dietary intake and biochemical values such as the serum
retinol concentration. IS All of these methods have tech-
nical and practical limitations and are not universally
applicable for field use. The WHO has recommended
that if the serum retinol concentration (!J..g Idl) is used to
assess vitamin A starus, then the following criteria
should be used: 16 < 10, deficient; 10 - 19, low; 20 - 50,
normal; > 50, high. If more than 5% of the population
have levels below 10 !J..g/dl, then vitamin A deficiency is
a major public health problem. The immediate causes of
vitamin A deficiency are socio-economic, including food
insecurity and poveny, and a consequently decreased
intake of vitamin A-rich foods; recurrent acute and
chronic infections may also adversely affect vitamin A
status by limiting dietary intake; decreasing absorption
and increasing requirements of the vitamin.
The realisation that marginal vitamin A status is a
major problem in many countries has led a number of
international agencies, including the WHO and
UJ'-TICEF, to call for the worldwide elimination of vita-
min A deficiency by the year 2000. Intervention strate-
gies to combat vitamin A deficiency include regular vita-
min A supplementation in the form of capsules through
a comprehensive or disease-targeted programme (cap-
sules are usually given every 4-6 months at doses varying
from 50 000 IV to 200 000 IU), food fortification (the
addition of vitamin A to regularly consumed foodstuffs
such as sugar, salt, cereals, milk and tea) as well as
dietary diversification and nutrition education with
regard to the consumption of vitamin A-rich foods.
In the absence of accurate national and regional data
on the vitamin A status of children in South Africa, it is
debatable17 whether a comprehensive capsule distribu-
tion programme or food fortification policy should be
recommended or not. IS The formulation of a vitamin A
policy for South Africa is currently being addressed by a
national group, the South African Vitamin A Study
Group, which includes representatives from different
regions, universities and the Department of Health. The
group is about to embark on a national survey of vita-
min A status in children, and plans to make recommen-
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dations to the Depamnem of Health on the adoption of
appropriate means for the improvemem of vitamin A
starus.
In the meantime and until such policy is fonnulated,
dietary diversification and consumption of vitamin A-
rich foods should be encouraged in all individuals and
communities; education on vitamin A should also be
part of any nutrition education programme. Should sup-
plementation be deemed necessary on clinical grounds,
e.g. in children with measles, malnutrition, chronic diar-
rhoea and pneumonia, a dose of 200 000 IU for child-
ren older than 1 year or 100 000 IU for children less
than 1 year of age should be given. In children under
the age of 6 months, vitamin A supplements hould be
used with extreme caution and no more than a single
50 000 IU dose should be given within a 6-month
period. It should be appreciated, and not forgotten, that
high doses of vitamin A may have adverse effects and
that supplementation should not be given without a
doctor's prescription.'9 Excessive use of vitamin A can
lead to acure toxicity - irritability or drowsiness, head-
ache, vomiting, inco-ordination, muscular weakness,
bulging of fontanelles (neonates), blurring of vision
(diplopia) and peeling of skin.'9.20 As such, should a large
dose of viramin A be given, it should be recorded in the
patient's notes and on the clinic's immunisation card.
This will prevent excessive dosing and its possible ad-
verse consequences. The daily intake of vitamin A in the
fonn of multivitamin preparations (I 500 - 5 000 IV) is
generally known to have an acceptable safety margin.
D. LABADARJOS
Deparnnent of Human Nutrition
University of Stellenboscb
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Controversial aspects of intravenous corticosteroids
in acute severe asthma
me aims of treatment in acute severe asthma areto decrease the incidence of relapses, morbidityand mortality as well as to promote recovery.'
It was pointed out in a recent review on fatal asthma
that the instirution of appropriate therapy and careful
monitoring of response could have a major impact on
morbidity and mortality from asthma.' The important
question is to decide what constitutes 'appropriate
therapy>. This article reappraises the role of parenteral
corticosteroids in acute asthma in the light of the con-
troversies that have been noted in the recent literature
on the subject.
Corricosteroids have been used to treat bronchial
asthma since the 1950s. In the very early work on acute
asthma by the British Medical Research Council,'
steroids were used in a controlled trial and found to be
effective, but the number of patients in this study was
small. In fact, patients with gradually deteriorating
asthma rather than acute severe asthma were used and
patients were also treated with sedatives. In addition,
the steroid dosages were physiological rather than phar-
macological and included oral steroids.
At least seven trials in the past 17 years showed
a benefit from intravenous steroids in acute severe
asthma.4-'O In five of the srudies patient numbers were
small although statistically significant increases in forced
expiratory volume in the first second (FEV,) in the
steroid-treated group were reported. In one of the larger
studies, Linenberg and Gluck" studied 97 acutely ill
patients with bronchial asthma in a double-blind,
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placebo-controlled, randomised trial of intravenous
methylprednisolone (125 mg) given on presentation in
the emergency room. Nineteen per cent of patients
treated with methylprednisolone required hospital
admission compared with 47% of patients in the control
group (P < 0,003). In this smdy the differences in FEV,
and FVC between the steroid-treated and the placebo
group were not statistically significant.
Pierson er al.7 had demonstrated in a placebo-con-
trolled smdy of 45 paediatric patients that there was
response to corticosteroids irrespective of the type used
(betamethasone, hydrocortisone, dexamethasone). In
addition, this smdy demonstrated that arterial hypox-
aemia improved in the patients treated with steroids.
It appears that the current practice of using high
doses of intravenous hydrocortisone (usually 200 mg 4-
hourly) was based on the smdy by Collins er al.' In this
smdy 23 patients with acute severe asthma were given
intravenous hydrocortisone in a dose of 3 mg/kg body
weight every 6 hours. The limitations of this smdy were
the absence of a control group and the small number of
patients. It was notable that objective evidence of
improvement in these patients did not appear until 6
hours after the stan of treannent.
A further factor in favour of the use of steroids in
acute severe asthma is that intravenous prednisolone
was found to restore adrenergic responsiveness. II This
may be advantageous in patients who show a poor bron-
chodilator response to [3radrenoreceptor stimulants.
Surprisingly, recent smdies found no benefit from
intravenous corticosteroids in patients with acute severe
asthma compared to controls in whom steroids were not
used.",13 To add further evidence to the possibility that
the role of steroids may have been overestimated in
acute asthma a few smdies have shown that there is no
difference in spirometry regardless of the steroid dose
used compared to controls. 14,15
The side-effects of intravenous steroids in acute
severe asthma may be aggravated by unnecessarily high
doses. One of the disturbing side-effects of steroids in
acute asthma is steroid-induced myopathy.16.21 In a
report by Sheel6 4 out of 9 patients ventilated for acute
asthma developed hydrocortisone-associated myopathy.
The hallmarks of corticosteroid myopathy in asthma are
normal creatine kinase levels" and predominantly pain-
less proximal muscle weakness.'6 Type IT fibre atrophy is
the commonest pathological abnormality demon-
strated." Steroid myopathy is not selective for the type
of steroid used, but most cases have occurred in patients
given high doses of steroids while on mechanical venti-
lation. It is posmlated that neuromuscular blockade,
due to the paralytic agents used during mechanical ven-
tilation may contribute in some way to steroid myo-
pathy.16 Recovery of muscle power can take 6 weeks to 6
months. 16,21
Worsening of asthma in aspirin-sensitive individuals
given hydrocortisone intravenously has also been
noted." Possibly other cases have occurred and the
increased airflow obstruction may have been anributed
to progression of asthma rather than to steroids. There
should be an increased awareness of the problem of
worsening airflow obstruction in aspirin-sensitive
patients given intravenous hydrocortisone.
There are no prospective placebo-controlled trials
showing that emergency room treatment of acute
asthma with intravenous corticosteroids reduced asthma
mortality. I
With the above information it is tempting to suggest
that in the acute attack of asthma intravenous cortico-
steroids may noL be necessary. In the acute attack bron-
chodilator therapy is likely to mask any beneficial effects
of steroids and this issue needs to be examined in future
studies. There is evidence that steroids improve the
responsiveness of [3?-agonists in the acute stage. I,ll If
parenteral corticoste;oids are beneficial in acute asthma
the optimal dose still needs to be determined.
In the light of the controversies surrounding the use
of intravenous conicosteroids for acute asthma we
would like to recommend that most patients with mild
to moderate attacks probably only require a loading
dose of 30-60 mg oral prednisolone (or equivalent). In
patients with severe exacerbations of asthma the large
doses of intravenous corticosteroids currently recom-
mended may be excessive and 100 mg hydrocortisone
6-hourIy or equivalent may be adequate. This would
result in a reduction of acute steroid side-effects and
cost. Patients recovering from an acute asthma attack
should be given a shott course of oral corticosteroids to
prevent relapses." The issue relating to the use of intra-
venous corticosteroids in acute asthma is still controver-
sial and a placebo-controlled trial with large numbers of
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A word of thanks to the reviewers for 1993
The quality of any scientific journal is determined to a
large extent by the quality of its peer review. In this
respect, the SAMJ considers itself vety fortunate indeed
to have had at its disposal in 1993 a panel of recognised
experts to serve as referees for manuscripts submitted
to us. Refereeing is a time-consuming and frequently
thankless exercise, and the SAMJ takes this opportu-
nity formally to express its gratitude to those listed
below who served as reviewers during 1993.
Although the Editor plans to write a more informa-
tive editorial on our selection process in the new year, it
will interest the reviewers to know that of the
manuscripts received in 1993, about 30% were recom-
mended for acceptance, another 30% were rejected
outright, and the rest were either converted to letters to
the editor, or recommended for specialist journals.
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A million tickets to Disneyland - the tragedy of the AIDS children
World AIDS Day seems to have passed relatively un-
noticed by the general populace, and this probably
applies to the medical community as well, except for
those directly involved with AIDS education, treatment
and counselling.
The apathy which seems to greet any talk of AIDS
and the disaster facing our country is frightening: it
may be due to the 'ostrich' syndrome, but we have to
get our heads our of the sand and face the truth sooner
or later; it may be due to lack" of experience with HIV-
positive individuals or those with full-blown AIDS; it
may be due to ignorance.
All these problems will be addressed by an inte-
grated campaign in SAMJ and CME during the coming
year.
We will be including loose inserts in SAMJ which
will deal with various aspects of counselling and
management of HIV-positive patients. The material
will be provided by the Western Province AIDS
Training Information and Counselling Centre, in con-
junction with other organisations. These inserts will be
linked with a series of articles in CME in alternate
months, from the same sources, expanding on the
material in the inserts. It is hoped that this campaign
will add to the knowledge of the medical practitioners
in South Africa, and will help to contain this plague
which threatens us all.
It may nor be clear what Disneyland has to do with
AIDS. Let me explain: in a television special broadcast
on M-Net on World AIDS Day, an HIV-positive little
boy of 6 was interviewed. He had contracted AIDS
from his mother, who did nor even realise that she was
HIV-positive until her son's test results were received.
She was subsequently tested and it turned out that she
had been infected by a college boyfriend who had been
a drug addict.
The little boy was asked by the interviewer, 'What
do you think heaven is like?'
He replied, 'It's like going to Disneyland with a
million tickets - and you can ride on anything as much
as you want.' He seemed unaware of his impending
suffering but one could only pray that his remaining
time would nor be too excruciating.
The tragedy of the children affected by the HIV -
both those who are orphaned and those who are in-
fected - is something that the medical community and
the rest of society are going to have to face and cope
with for many years to come. This is apan from the
already well-known and widely predicted effects on the
economy, health services and other community-based
organisations.
The active participation of doctors in education,
prevention and proper management is essential if the
human race is to survive with any semblance of opti-
mism.
Don't deny the facts; don't bury your heads in the
sand; and take every oPPQnunity to educate yourselves_
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A million tickets to Disneyland - the tragedy of the AIDS children
World AIDS Day seems ro have passed relatively un-
noticed by the general populace, and this probably
applies ro the medical community as well, except for
those directly involved with AIDS education, treatment
and counselling. .
The apathy which seems ro greer any ralk of AIDS
and the disaster facing our country is frighrening: ir
may be due ro the 'ostrich' syndrome, bur we have ro
ger our heads out of the sand and face the truth sooner
or later; it may be due ro lack of experience with HIV-
positive individuals or those with full-blown AIDS; ir
may be due ro ignorance.
All these problems will be addressed by an inte-
grated campaign in SAM] and CME during the coming
year.
We will be including loose insens in SAM] which
will deal with various aspects of counselling and
management of HIV-positive patients. The material
will be provided by rhe Western Province AIDS
Training Information and Counselling Centre, in con-
junction with other organisations. These insens will be
linked with a series of articles in CME in alternate
months, from rhe same sources, expanding on rhe
material in the insens. It is hoped that this campaign
will add ro the knowledge of the medical practitioners
in South Africa, and will help ro contain this plague
which threarens us all.
It may not be clear what Disneyland has ro do with
AIDS. Let me explain: in a television special broadcast
on M-Net on World AIDS Day, an HIV-positive lime
boy of 6 was interviewed. He had contracted AIDS
from his mother, who did not even realise that she was
HIV-positive until her son's test results were received.
She was subsequently tested and it turned out that she
had been infected by a college boyfriend who had been
a drug addict.
The lime boy was asked by the interviewer, 'What
do vou think heaven is like?'
He replied, 'It's like going to Disneyland with a
million tickets - and you can ride on anything as much
as you want.' He seemed unaware of his impending
suffering but one could only pray that his remaining
time would not be roo excruciating.
The tragedy of the children affected by the HIV -
both those who are orphaned and those who are in-
fected - is something that the medical community and
the rest of society are going ro have ro face and cope
with for many years to come. This is apart from the
already well-known and widely predicted effects on the
economy, health services and other community-based
organisations.
The active participation of doctors in education,
prevention and proper management is essential if the
human race is to survive with any semblance of opti-
mIsm.
Don't deny the facts; don't bury your heads in the
sand; and take every oPPQnunity to educate yourselves_
SAM] and CME are there to help. Use them.
F. N. SANDERS
